FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction; Stiolto Respimat is the first in its class to have exacerbation data in the product labeling

Press/Media: Press / Media

PeriodOct 11 2018

Media coverage

2

Media coverage

  • TitleFDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction; Stiolto Respimat is the first in its class to have exacerbation data in the product labeling
    Media name/outletPR Newswire
    CountryUnited States
    Date10/11/18
    PersonsAntonio R Anzueto
  • TitleFDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction; Stiolto Respimat is the first in its class to have exacerbation data in the product labeling
    Media name/outletPR Newswire
    CountryUnited States
    Date10/11/18
    PersonsAntonio R Anzueto